Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)
NCT07193550Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2025
- Primary completion
- Oct 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of zanzalintinib in bone sarcoma, sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
bone sarcoma
Beyond the preview
Go deeper on NCT07193550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193550.